2024
Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2022
Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder
Holmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in Quantification of the Metabotropic Glutamate Receptor 5 Across Bipolar Disorder and Major Depressive Disorder. Biological Psychiatry 2022, 93: 1099-1107. PMID: 36764853, PMCID: PMC10164841, DOI: 10.1016/j.biopsych.2022.10.018.Peer-Reviewed Original ResearchConceptsMajor depressive disorderMetabotropic glutamate receptor 5Glutamate receptor 5MGluR5 availabilityBipolar disorderPositron emission tomographyHC groupDepressive disorderReceptor 5Emission tomographyHealthy control individualsPossible treatment targetsGlutamate transmissionBD depressionTreatment strategiesBD groupMGluR5Depressive symptomsNovel treatmentsCognitive alterationsTreatment targetsSynaptic plasticityControl individualsAccurate diagnosisSignificant negative correlation
2021
Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder
Davis MT, DellaGiogia N, Maruff P, Pietrzak RH, Esterlis I. Acute cognitive effects of single-dose intravenous ketamine in major depressive and posttraumatic stress disorder. Translational Psychiatry 2021, 11: 205. PMID: 33833217, PMCID: PMC8032778, DOI: 10.1038/s41398-021-01327-5.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderExecutive functionStress disorderCognitive functionSingle-dose intravenous ketamineAcute cognitive effectsLarge magnitude improvementsPTSD relativeCognitive measuresCognitive domainsPTSD individualsMemory performanceCognitive effectsYears of educationBaseline performanceCognitive declineHealthy controlsPsychiatric distressCognitive dysfunctionHC individualsHC groupDepressive symptomsMemory 2Subanesthetic doseMajor depressive
2020
Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression
Dai D, Lacadie CM, Holmes SE, Cool R, Anticevic A, Averill C, Abdallah C, Esterlis I. Ketamine Normalizes the Structural Alterations of Inferior Frontal Gyrus in Depression. Chronic Stress 2020, 4: 2470547020980681. PMID: 33426409, PMCID: PMC7758564, DOI: 10.1177/2470547020980681.Peer-Reviewed Original ResearchMajor depressive disorderPost-traumatic stress disorderMagnetic resonance imagingAcute ketamine administrationKetamine administrationKetamine infusionMDD subjectsInferior frontal gyrusComorbid post-traumatic stress disorderPTSD groupAcute ketamine treatmentFrontal gyrusHealthy control subjectsIntravenous ketamine infusionRegional volume differencesImpact of ketamineSingle ketamine infusionStructural alterationsFuture therapeutic targetsVoxel-wise t-testsKetamine treatmentControl subjectsDepressive disorderHC groupPTSD subjects